Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Silvia de Muga"'
Autor:
Roberto Martínez, Gustavo Tapia, Silvia De Muga, Alba Hernández, Maria González Cao, Cristina Teixidó, Victor Urrea, Elisabet García, Sònia Pedreño-López, Luis Ibarz, Julià Blanco, Bonaventura Clotet, Cecilia Cabrera
Publikováno v:
OncoImmunology, Vol 8, Iss 8 (2019)
Intravesical Bacille Calmette-Guérin (BCG) remains the most effective treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), unfortunately there is no validated biomarker to predict clinical outcome. Here we tried to explore the possibi
Externí odkaz:
https://doaj.org/article/ee255589556345598314c93c2dd3c356
Autor:
Joaquim Bellmunt, Shamini Selvarajah, Scott Rodig, Marta Salido, Silvia de Muga, Irmgard Costa, Beatriz Bellosillo, Lillian Werner, Stephanie Mullane, André P Fay, Robert O'Brien, Jordi Barretina, André E Minoche, Sabina Signoretti, Clara Montagut, Heinz Himmelbauer, David M Berman, Philip Kantoff, Toni K Choueiri, Jonathan E Rosenberg
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e103325 (2014)
BACKGROUND: Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene alterations in urothelial carcinom
Externí odkaz:
https://doaj.org/article/bbf5118d3ed9435c9fbb95822615c00c
Autor:
Lluís Cecchini, Alba Font-Tello, Silvia Hernández-Llodrà, Albert Francés, Nuria Juanpere, Silvia de Muga, Marta Lorenzo, Josep Lloreta, Lara Nonell, Ivonne Vázquez
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
instname
Nuclear FOXOs mediate cell cycle arrest and promote apoptosis. FOXOs and p53 could have similar effects as tumor suppressor genes. In spite of extensive literature, little is known about the role of FOXO1 and its relationship with p53 status in bladd
Autor:
Maria Gonzalez Cao, Sònia Pedreño-López, Cristina Teixidó, Roberto Martinez, Gustavo Tapia, Silvia De Muga, Alba Hernández, Julià Blanco, Bonaventura Clotet, Luis Ibarz, Cecilia Cabrera, Elisabet García, Victor Urrea
Publikováno v:
OncoImmunology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
OncoImmunology, Vol 8, Iss 8 (2019)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
OncoImmunology, Vol 8, Iss 8 (2019)
Intravesical Bacille Calmette-Guerin (BCG) remains the most effective treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), unfortunately there is no validated biomarker to predict clinical outcome. Here we tried to explore the possibil
Autor:
Nuria Juanpere, Lluís Cecchini, Lluís Fumadó, Silvia de Muga, Laia Serrano, Josep Lloreta, Sergio Serrano, Marta Salido, Alba Font-Tello, Marta Lorenzo, Silvia Hernández
Publikováno v:
The Prostate. 76:854-865
BACKGROUND SLC45A3 is the second most common ERG partner in prostate cancer (PrCa). Coexisting TMPRSS2 and SLC45A3 rearrangements are found in a subset of cases, but the meaning is still unknown. METHODS SLC45A3-ERG and TMPRSS2-ERG rearrangements and
Autor:
Sergio Serrano, Laia Serrano, Nuria Juanpere, Silvia Hernández, Alba Font-Tello, José A. Lorente, Marta Lorenzo, Silvia de Muga, Josep Lloreta, Lluís Fumadó
Publikováno v:
The Prostate. 75:1216-1226
BACKGROUND There is controversy in the literature on the role of the fusion TMPRSS2-ERG in the pathogenesis and progression of prostate cancer. The quantitative differences in TMPRSS2-ERG fusion expression have received very limited attention in the
Autor:
Rachel S. Park, Enrique Gallardo, André P. Fay, Joaquim Bellmunt, Jonathan E. Rosenberg, Lillian Werner, Massimo Loda, Markus Riester, Richard Martin Bambury, Elizabeth A. Guancial, David M. Berman, Silvia de Muga, Toni K. Choueiri, Stephanie A. Mullane, Justine A. Barletta, Aristotle Bamias, Edward C. Stack, Shamini Selvarajah, Federico Rojo, Marta Salido
Publikováno v:
Cancer Medicine
Repositório Institucional PUCRS
Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
instacron:PUC_RS
Repositório Institucional PUCRS
Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
instacron:PUC_RS
We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of ≥2.2) by immunohistochemistry
Autor:
Laura Segalés, Silvia de Muga, Silvia Hernández-Llodrà, Laia Serrano, Lluís Fumadó, Raquel Albero-González, Alba Font-Tello, Marta Lorenzo, José Merino, Josep Lloreta Trull, Lluís Cecchini, Nuria Juanpere, Laia Agell, Joan Gil
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
Oncotarget
instname
Oncotarget
// Silvia Hernandez-Llodra 1, * , Nuria Juanpere 1, 2, * , Silvia de Muga 1 , Marta Lorenzo 2 , Joan Gil 1 , Alba Font-Tello 3 , Laia Agell 1 , Raquel Albero-Gonzalez 2 , Laura Segales 1 , Jose Merino 4 , Laia Serrano 2 , Lluis Fumado 5 , Lluis Cecch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::960b80f59aa66c5e3199040b1bce0b6e
http://hdl.handle.net/10230/34219
http://hdl.handle.net/10230/34219
Autor:
José A. Lorente, Silvia de Muga, Sergio Serrano, Josep Lloreta, Marta Salido, Marta Lorenzo, Nuria Juanpere, Laia Agell, Silvia Hernández
Publikováno v:
Cancer Biomarkers. 12:21-30
T heTMPRSS2-ERG fusion has been reported in 42 to 78% of prostate tumors. More than 90% of ERG-overexpressing tumors harbor the fusion. The relationship between the TMPRSS2-ERG fusion and prognosis is controversial. Different studies have suggested a
Autor:
Lara Nonell, José A. Lorente, Silvia de Muga, Eulàlia Puigdecanet, Pedro L. Fernández, Sergio Serrano, Josep Lloreta, Raquel Bermudo, Marta Lorenzo, Laia Agell, Nuria Juanpere, Silvia Hernández
Publikováno v:
The American Journal of Pathology. 181:1585-1594
The main challenge for clinical management of prostate cancer is to distinguish tumors that will progress faster and will show a higher tendency to recur from the more indolent ones. We have compared expression profiles of 18 prostate cancer samples